Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

被引：477

作者：

Jeon, Sangeun ^{[1
]}

Ko, Meehyun ^{[1
]}

Lee, Jihye ^{[1
]}

Choi, Inhee ^{[2
]}

Byun, Soo Young ^{[3
]}

Park, Soonju ^{[3
]}

Shum, David ^{[3
]}

Kim, Seungtaek ^{[1
]}

机构：

[1] Inst Pasteur Korea, Zoonot Virus Lab, Seongnam, South Korea

[2] Inst Pasteur Korea, Med Chem, Seongnam, South Korea

[3] Inst Pasteur Korea, Screening Discovery Platform, Seongnam, South Korea

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 07期

基金：

新加坡国家研究基金会;

关键词：

COVID-19; FDA-approved drug; SARS-CoV-2; CICLESONIDE;

D O I：

10.1128/AAC.00819-20

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.

引用

页数：9

共 14 条

[1] Drug repositioning: Identifying and developing new uses for existing drugs [J].

Ashburn, TT ;

Thor, KB .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683

[2]

Beck BR, 2020, BIORXIV, DOI [10.1101/2020.01.31.929547, DOI 10.1101/2020.01.31.929547, 10.1101/2020.01.31.929547.]

[3] SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection [J].

Gassen, Nils C. ;

Niemeyer, Daniela ;

Muth, Doreen ;

Corman, Victor M. ;

Martinelli, Silvia ;

Gassen, Alwine ;

Hafner, Kathrin ;

Papies, Jan ;

Moesbauer, Kirstin ;

Zellner, Andreas ;

Zannas, Anthony S. ;

Herrmann, Alexander ;

Holsboer, Florian ;

Brack-Werner, Ruth ;

Boshart, Michael ;

Mueller-Myhsok, Bertram ;

Drosten, Christian ;

Mueller, Marcel A. ;

Rein, Theo .

NATURE COMMUNICATIONS, 2019, 10 (1)

[4] Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases [J].

Iwabuchi, Keisuke ;

Yoshie, Koichiro ;

Kurakami, Yuichi ;

Takahashi, Kota ;

Kato, Yoshio ;

Morishima, Tsuneo .

JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (06) :625-632

[5] Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia [J].

Li, Qun ;

Guan, Xuhua ;

Wu, Peng ;

Wang, Xiaoye ;

Zhou, Lei ;

Tong, Yeqing ;

Ren, Ruiqi ;

Leung, Kathy S. M. ;

Lau, Eric H. Y. ;

Wong, Jessica Y. ;

Xing, Xuesen ;

Xiang, Nijuan ;

Wu, Yang ;

Li, Chao ;

Chen, Qi ;

Li, Dan ;

Liu, Tian ;

Zhao, Jing ;

Liu, Man ;

Tu, Wenxiao ;

Chen, Chuding ;

Jin, Lianmei ;

Yang, Rui ;

Wang, Qi ;

Zhou, Suhua ;

Wang, Rui ;

Liu, Hui ;

Luo, Yinbo ;

Liu, Yuan ;

Shao, Ge ;

Li, Huan ;

Tao, Zhongfa ;

Yang, Yang ;

Deng, Zhiqiang ;

Liu, Boxi ;

Ma, Zhitao ;

Zhang, Yanping ;

Shi, Guoqing ;

Lam, Tommy T. Y. ;

Wu, Joseph T. ;

Gao, George F. ;

Cowling, Benjamin J. ;

Yang, Bo ;

Leung, Gabriel M. ;

Feng, Zijian .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (13) :1199-1207

[6]

Mao LJ, 2020, BMC INFECT DIS, V20, DOI [10.1186/s12879-020-05056-w, 10.1186/s12879-020-05072-w]

[7]

Matsuyama S., 2020, BIORXIV, DOI 10.1101/2020.03.11.987016

[8] The next chapter for African genomics [J].

Maxmen, Amy .

NATURE, 2020, 578 (7795) :350-354

[9]

Mizumoto K, 2020, ESTIMATING RISK 2019, DOI [10.1101/2020.02.19.20025163, DOI 10.1101/2020.02.19.20025163]

[10]

Schaffner TJ, 2009, J ASTHMA ALLERGY, V2, P25

← 1 2 →